CLINICAL_TRIALS
trial_result
· 2016-04-13
Clinical Trial Update: VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis [Phase 2]
Summary
A Phase 2 dose-ranging trial (VELVET) evaluating veltuzumab in adults with moderate to severe rheumatoid arthritis was terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Takeda | Conditions: Rheumatoid Arthritis | Phase 2 | Status: TERMINATED